Immunisations in Crohn's disease: Who? Why? What? When?

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 3, 2014, Pages 485-496

  Magro, F ^a,b,c   Abreu, C ^b,c  

^a University of Porto   (Portugal)

^b Universidade do Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Crohn disease; Efficacy; Immunomodulator medication; Immunosuppression; Inflammatory bowel disease; Risk of infection; Vaccines

Indexed keywords

ADALIMUMAB; BIOLOGICAL FACTOR; CHICKENPOX VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; HEPATITIS A; HEPATITIS B; HOUSEHOLD; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; INFECTION RISK; INTUSSUSCEPTION; MORTALITY; NONHUMAN; TRAVEL; VACCINATION;

CROHN DISEASE; EFFICACY; IMMUNOMODULATOR MEDICATION; IMMUNOSUPPRESSION; INFLAMMATORY BOWEL DISEASE; RISK OF INFECTION; VACCINES;

COMMUNICABLE DISEASE CONTROL; CROHN DISEASE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOSUPPRESSIVE AGENTS; VACCINES;

EID: 84902255144     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.04.007     Document Type: Review

References (75)

1. S.L. Plotkin, and S.A. Plotkin A short history of vaccination 4th ed. 2004 Philadelphia
2. A.C. Ford, and L. Peyrin-Biroulet Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials Am J Gastroenterol 108 8 2013 1268 1276
3. D.J.B. Marks Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity? Curr Opin Gastroenterol 27 4 2011 328 334
4. B.E. Sands, C. Cuffari, J. Katz, S. Kugathasan, J. Onken, and C. Vitek et al. Guidelines for immunizations in patients with inflammatory bowel disease Inflamm Bowel Dis 10 5 2004 677 692
5. J.-F. Rahier, M. Moutschen, A. Van Gompel, M. Van Ranst, E. Louis, and S. Segaert et al. Vaccinations in patients with immune-mediated inflammatory diseases Rheumatology 49 10 2010 1815 1827
6. S.K. Wasan, S.E. Baker, P.R. Skolnik, and F.A. Farraye A practical guide to vaccinating the inflammatory bowel disease patient Am J Gastroenterol 105 6 2010 1231 1238
7. V. Wilckens, K. Kannengiesser, K. Hoxhold, C. Frenkel, T. Kucharzik, and C. Maaser The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines Scand J Gastroenterol 46 7-8 2011 855 861
8. S.K. Wasan, J.A. Coukos, and F.A. Farraye Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge Inflamm Bowel Dis 17 12 2011 2536 2540
9. J. Burisch, N. Pedersen, S. Cukovic-Cavka, N. Turk, I. Kaimakliotis, and D. Duricova et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in europe: the ECCO-EpiCom cohort Inflamm Bowel Dis 20 1 2014 36 46
10. J.D. Grabenstein Targeting vaccines to specific clusters of people Hosp Pharm 1999 8
11. G. Gupta, E. Lautenbach, and J.D. Lewis Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease Clin Gastroenterol Hepatol 4 12 2006 1483 1490
12. E. Derhovanessian, and G. Pawelec Vaccination in the elderly Microb Biotechnol 5 2 2012 226 232
13. B. Weinberger, and B. Grubeck-Loebenstein Vaccines for the elderly Clin Microbiol Infect 18 Suppl. 5 2012 100 108 [Epub 2012/08/07]
14. A.T. Kroger, W.L. Atkinson, E.K. Marcuse, L.K. Pickering Advisory Committee on Immunization Practices Centers for D, Control, Prevention General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 55 RR-15 2006 1 48
15. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine [Reprinted from MMWR, vol 60, pg 1279-1280, 2011] JAMA 306 17 2011 1856 1857
16. I. Dotan, L. Werner, S. Vigodman, S. Agarwal, J. Pfeffer, and N. Horowitz et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines Inflamm Bowel Dis 18 2 2012 261 268
17. M.D. Brogan, F. Shanahan, M. Oliver, R.H. Stevens, and S.R. Targan Defective memory B-cell formation in patients with inflammatory bowel-disease following tetanus toxoid booster immunization J Clin Lab Immunol 24 2 1987 69 74
18. S. Dezfoli, and G.Y. Melmed Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression Gastroenterol Hepatol 8 8 2012 504 512
19. J.P. Gisbert, L. Menchen, V. Garcia-Sanchez, I. Marin, J.R. Villagrasa, and M. Chaparro Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease Aliment Pharmacol Ther 35 12 2012 1379 1385
20. M.E. Altunoz, E. Senates, A. Yesil, T. Calhan, and A.O.K. Ovunc Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls Dig Dis Sci 57 4 2012 1039 1044
21. S.M. Lemon, and D.L. Thomas Drug therapy - vaccines to prevent viral hepatitis N Engl J Med 336 3 1997 196 204
22. H.D. Nothdurft, M. Dietrich, J.N. Zuckerman, J. Knobloch, P. Kern, and J. Vollmar et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B Vaccine 20 7-8 2002 1157 1162
23. B.A. Connor, M.M. Blatter, J. Beran, B. Zou, and A.F. Trofa Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule J Travel Med 14 1 2007 9 15
24. F.E. Shaw, H.A. Guess, J.M. Roets, F.E. Mohr, P.J. Coleman, and E.J. Mandel et al. Effect of anatomic injection site, age and smoking on the immune-response to hepatitis-B vaccination Vaccine 7 5 1989 425 430
25. D.J. Weber, W.A. Rutala, G.P. Samsa, J.E. Santimaw, and S.M. Lemon Obesity as a predictor of poor antibody-response to hepatitis-B plasma vaccine JAMA 254 22 1985 3187 3189
26. C.A. Alper, M.S. Kruskall, D. Marcusbagley, D.E. Craven, A.J. Katz, and S.J. Brink et al. Genetic prediction of nonresponse to hepatitis-B vaccine N Engl J Med 321 11 1989 708 712
27. F. Averhoff, F. Mahoney, P. Coleman, G. Schatz, E. Hurwitz, and H. Margolis Immunogenicity of hepatitis B vaccines - implications for persons at occupational risk of hepatitis B virus infection Am J Prev Med 15 1 1998 1 8
28. R.C. Wood, K.L. Macdonald, K.E. White, C.W. Hedberg, M. Hanson, and M.T. Osterholm Risk-factors for lack of detectable antibody following hepatitis-B vaccination of Minnesota health-care workers JAMA 270 24 1993 2935 2939
29. B.A. Zajac, D.J. West, W.J. McAleer, and E.M. Scolnick Overview of clinical-studies with hepatitis-B vaccine made by recombinant-DNA J Infect 13 1986 39 45
30. E.E. Mast, C.M. Weinbaum, A.E. Fiore, M.J. Alter, B.P. Bell, L. Finelli Advisory Committee on Immunization Practices Centers for D, Control, Prevention A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults MMWR Recomm Rep 55 RR-16 2006 1 33 quiz CE1-4
31. J.S. Bertino, P. Tirrell, R.N. Greenberg, H.L. Keyserling, G.A. Poland, and D. Gump et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S-1, and pre-S-2 particles for revaccination of healthy adult nonresponders J Infect Dis 175 3 1997 678 681
32. K. Cardell, B. Akerlind, M. Sallberg, and A. Fryden Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine J Infect Dis 198 3 2008 299 304
33. B.P. Bell, D. Kruszon-Moran, C.N. Shapiro, S.B. Lambert, G.M. McQuillan, and H.S. Margolis Hepatitis A virus infection in the United States: serologic results from the third National Health and Nutrition Examination Survey Vaccine 23 50 2005 5798 5806
34. P. Van Damme, J. Banatvala, O. Fay, S. Iwarson, B. McMahon, K. Van Herck Int Consensus Grp Hepatitis AV Hepatitis A booster vaccination: is there a need? Lancet 362 9389 2003 1065 1071
35. A. Radzikowski, A. Banaszkiewicz, I. Lazowska-Przeorek, U. Grzybowska-Chlebowczyk, H. Wos, and T. Pytrus et al. Immunogenecity of hepatitis a vaccine in pediatric patients with inflammatory bowel disease Inflamm Bowel Dis 17 5 2011 1117 1124
36. S.M. Lemon, and L.N. Binn Serum neutralizing antibody-response to hepatitis-A virus J Infect Dis 148 6 1983 1033 1039
37. J.A. Dumot, D.S. Barnes, Z. Younossi, S.M. Gordon, R.K. Avery, and R.E. Domen et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease Am J Gastroenterol 94 6 1999 1601 1604
38. M. Arslan, R.H. Wiesner, J.J. Poterucha, and N.N. Zein Safety and efficacy of hepatitis A vaccination in liver transplantation recipients Transplantation 72 2 2001 272 276
39. Centers for Disease C, Prevention Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014 MMWR Recomm Rep 62 RR-07 2013 1 43
40. A. Chalmers, D. Scheifele, C. Patterson, D. Williams, J. Weber, and R. Shuckett et al. Immunization of patients with rheumatoid-arthritis against influenza - a study of vaccine safety and immunogenicity J Rheumatol 21 7 1994 1203 1206
41. N. Agarwal, K. Ollington, M. Kaneshiro, R. Frenck, and G.Y. Melmed Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review Vaccine 30 8 2012 1413 1424 [Epub 2011/12/27]
42. P. Mamula, J.E. Markowitz, D.A. Piccoli, A. Klimov, L. Cohen, and R.N. Baldassano Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease Clin Gastroenterol Hepatol 5 7 2007 851 856
43. Y. Lu, D.L. Jacobson, L.A. Ashworth, R.J. Grand, A.L. Meyer, and M.M. McNeal et al. Immune response to influenza vaccine in children with inflammatory bowel disease Am J Gastroenterol 104 2 2009 444 453
44. Centers for Disease C, Prevention, Advisory Committee on Immunization P Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23) MMWR Morb Mortal Wkly Rep 59 34 2010 1102 1106
45. G.Y. Melmed, R. Frenck, C. Barolet-Garcia, P. Ibanez, P. Simpson, and K.A. Papadakis et al. TNF blockers and immunomodulators impair antibody responses to pneumococcal polysaccharide vaccine (Ppv) in patients with inflammatory bowel disease (IBD) Gastroenterology 134 4 2008 A68
46. G.Y. Melmed, N. Agarwal, R.W. Frenck, A.F. Ippoliti, P. Ibanez, and K.A. Papadakis et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease Am J Gastroenterol 105 1 2010 148 154
47. G. Fiorino, L. Peyrin-Biroulet, P. Naccarato, H. Szabo, O.R. Sociale, and S. Vetrano et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study Inflamm Bowel Dis 18 6 2012 1042 1047
48. I. Heard Human papillomavirus, cancer and vaccination Curr Opin Hiv Aids 6 4 2011 297 302
49. S.T. Park, M.J. Song, J.S. Park, S.Y. Hur, and C.W. Lee Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients World J Surg Oncol 2011 9
50. N. Munoz, F.X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K.V. Shah Int Agcy Res Canc Multicenter C Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 6 2003 518 527
51. S. Kane, B. Khatibi, and D. Reddy Higher incidence of abnormal pap smears in women with inflammatory bowel disease Am J Gastroenterol 103 3 2008 631 636
52. E. Tamas, S. Mannor, and M. Shevchuk Cervical squamous lesions associated with ulcerative colitis Lab Invest 82 1 2002 212A A
53. J. Bhatia, J. Bratcher, B. Korelitz, K. Vakher, S. Mannor, and M. Shevchuk et al. Abnormalities of uterine cervix in women with inflammatory bowel disease World J Gastroenterol 12 38 2006 6167 6171
54. H. Singh, A.A. Demers, Z. Nugent, S.M. Mahmud, E.V. Kliewer, and C.N. Bernstein Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study Gastroenterology 136 2 2009 451 458
55. C.W. Lees, J. Critchley, N. Chee, T. Beez, R.E. Gailer, and A.R. Williams et al. Lack of association between cervical dysplasia and IBD: a large case-control study Inflamm Bowel Dis 15 11 2009 1621 1629
56. Centers for Disease C, Prevention FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 59 20 2010 626 629
57. Centers for Disease C Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 59 20 2010 630 632
58. Advisory Committee on Immunization P Recommended adult immunization schedule: United States, 2009* Ann Intern Med 150 1 2009 40 44
59. Y. Lu, L.A. Ashworth, A. Bousvaros, R. Carey, H.D. Renna, and D.L. Jacobson Immune response to human papillomavirus vaccine (Gardasil) in girls and young women with inflammatory bowel disease Gastroenterology 140 5 2011 S158 S159
60. H.Q. McLean, A.P. Fiebelkorn, J.L. Temte, and G.S. Wallace Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013 summary recommendations of the advisory committee on immunization practices (ACIP) MMWR Recomm Rep 62 4 2013 1 34
61. C.N. Kotton Vaccines and inflammatory bowel disease Dig Dis 28 3 2010 525 535
62. G.R. Lichtenstein, B.G. Feagan, R.D. Cohen, B.A. Salzberg, R.H. Diamond, and D.M. Chen et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry Clin Gastroenterol Hepatol 4 5 2006 621 630
63. V.S. Leung, M.T. Nguyen, and T.M. Bush disseminated primary varicella after initiation of infliximab for Crohn's disease Am J Gastroenterol 99 12 2004 2503 2504
64. S. Domm, J. Cinatl, and U. Mrowietz The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature Br J Dermatol 159 6 2008 1217 1228
65. R. Harpaz, I.R. Ortega-Sanchez, and J.F. Seward Advisory committee on immunization practices centers for D, control, prevention. Prevention of herpes zoster: recommendations of the Advisory committee on immunization Practices (ACIP) MMWR Recomm Rep 57 RR-5 2008 1 30 quiz CE2-4
66. J.F. Rahier, S. Ben-Horin, Y. Chowers, C. Conlon, P. De Munter, G. D'Haens ECCO European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease J Crohns Colitis 3 2 2009 47 91
67. Centers for Disease C, Prevention FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella MMWR Morb Mortal Wkly Rep 61 12 2012 212
68. MERK ZOSTAVAX (R) package insert 2006 Available from http://www.merck. com/product/usa/pi-circulars/z/zostavax/zostavax-pi2.pdf
69. M. Dubinsky, B. Abraham, and U. Mahadevan Management of the pregnant IBD patient Inflamm Bowel Dis 14 12 2008 1736 1750
70. F. Schnitzler, H. Fidder, M. Ferrante, V. Ballet, M. Noman, and G. Van Assche et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy Inflamm Bowel Dis 17 9 2011 1846 1854
71. U. Mahadevan, D.C. Wolf, M. Dubinsky, A. Cortot, S.D. Lee, and C.A. Siegel et al. Placental Transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease Clin Gastroenterol Hepatol 11 3 2013 286 292
72. Z. Zelinkova, C. de Haar, L. de Ridder, M.J. Pierik, E.J. Kuipers, and M.P. Peppelenbosch et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy Aliment Pharmacol Ther 33 9 2011 1053 1058
73. Z. Zelinkova, C. van der Ent, K.F. Bruin, O. van Baalen, H.G. Vermeulen, and H.J.T. Smalbraak et al. Dutch Delta IBDG. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure Clin Gastroenterol Hepatol 11 3 2013 318 321
74. J.P. Gisbert, and M.A. Chaparro Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease Am J Gastroenterol 108 9 2013 1426 1438
75. M.M. Cortese, U.D. Parashar Centers for Disease C, Prevention Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 58 RR-2 2009 1 25